Format

Send to

Choose Destination
Nat Rev Drug Discov. 2013 May;12(5):358-69. doi: 10.1038/nrd3979.

Implementing personalized cancer genomics in clinical trials.

Author information

1
Biometric Research Branch, US National Cancer Institute, Bethesda, Maryland 20892-7434, USA.

Abstract

The recent surge in high-throughput sequencing of cancer genomes has supported an expanding molecular classification of cancer. These studies have identified putative predictive biomarkers signifying aberrant oncogene pathway activation and may provide a rationale for matching patients with molecularly targeted therapies in clinical trials. Here, we discuss some of the challenges of adapting these data for rare cancers or molecular subsets of certain cancers, which will require aligning the availability of investigational agents, rapid turnaround of clinical grade sequencing, molecular eligibility and reconsidering clinical trial design and end points.

PMID:
23629504
DOI:
10.1038/nrd3979
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center